Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Efficacy and safety of deferasirox in myelodysplastic syndromes

    ... validated in prospective trials. The oral iron chelator, deferasirox , has been shown to reduce serum ferritin levels in ... independently from the efficacy on iron overload . Deferasirox is a potent NF-kB inhibitor, tested in vivo and on acute myeloid ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

    ... the first prospective study evaluating the effects of deferasirox on liver iron concentration (LIC), labile plasma iron ... total drug exposure. Data demonstrated that deferasirox was well tolerated and effectively reduced LIC, LPI and serum ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

    ... myelodysplastic syndromes (MDS) treated with deferasirox . A secondary objective was to investigate the relationship ... 159 patients, of whom 152 received at least one dose of deferasirox. HRQOL was assessed with the European Organisation for Research ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy

    ... complications and the use of ICT (primarily deferasirox ) to improve outcomes in patients with MDS. Expert commentary: ... survival benefit. Orally administered chelation agents (e.g. deferasirox) are now available, and observational and/or retrospective data ...

    Research Article last updated 07/18/2018 - 8:41am.

  5. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

    ... chelation therapy in selected patients is mandatory. Deferasirox (DFX) is an orally administered iron chelator which has been ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Iron chelation therapy in myelodysplastic syndromes.

    ... phlebotomy and ICT with agents such as deferoxamine and deferasirox . Data evaluating pharmacologic therapy for treatment of iron ... to implement and optimize ICT using deferoxamine and deferasirox will be important to provide optimal care for ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

    ... chelation therapy with either deferoxamine (41%), deferasirox (36%), and deferoxamine followed by deferasirox (23%). There were no statistically significant differences between ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes

    ... patients, 70% were chelated adequately mainly with deferasirox (26%) or deferasirox following deferoxamine (39%). Mortality was 70% among ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Iron overload in myelodysplastic syndromes: diagnosis and management.

    ... Iron chelation strategies include oral agents such as deferasirox (Exjade, Novartis Pharmaceuticals Corp, East Hanover, NJ), ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Deferasirox

    ... who get a lot of red blood cell transfusions. Deferasirox binds with the iron in the body and is removed by the kidneys. ...

    Drug last updated 04/01/2016 - 12:28pm.